Table 1 Clinical characteristics of intrabone UCB transplants
No. of patients | 23 | |
Years of transplant | 2009–2012 | |
Age | Median, range | 36 years (16–57) |
Gender | Males, % | 9 (39%) |
Interval diagnosis-transplant | Median, range | 10 months (4–60) |
Diagnosis | ||
AML, n (%) | 16 (69.6) | |
ALL, n (%) | 4 (17.4) | |
CML, n (%) | 1 (4.3) | |
NHL, n (%) | 1 (4.3) | |
MM, n (%) | 1 (4.3) | |
Phase at transplant | ||
1st Complete Remission (%) | 5 (21.7) | |
2nd Complete Remission (%) | 3 (13.0) | |
>2 Complete Remission (%) | 3 (13.0) | |
Primary Refractory (%) | 6 (26.1) | |
Resistant Relapse (%) | 4 (17.4) | |
Progression (for MM) (%) | 1 (4.3) | |
Blastic Phase (for CML) (%) | 1 (4.3) | |
Previous transplant | ||
Autologous, n of pts (%) | 6 (26.1) | |
Allogeneic, n of pts (%) | 3 (13.0) | |
Courses of therapy | Median, range | 4.5 months (2–7) |
Conditioning regimen | ||
Cy-TBI (%) | 3 (13.0) | |
Bu- Cy (%) | 11 (47.8) | |
Bu- Flu-TT (%) | 9 (39.2) | |
GVHD prophylaxis | ATG-CsA-MMF (%) | 23 (100.0) |
CMV serostatus | ||
Recipient Neg/Donor Neg, n (%) | 3 (13.0) | |
Recipient Pos/Donor Neg, n (%) | 20 (87.0) | |
Donor recipient HLA matching | ||
4/6, n (%) | 20 (87.0) | |
5/6, n (%) | 3 (13.0) | |
TNC×107/kg pre thawing | Median, range | 3.04 (1.91–5.48) |
TNC×107/kg infused | Median, range | 2.06 (0.20–3.92) |
CD34 + cells×105/kg pre thawing | Median, range | 1.29 (0.12–3.46) |
CD34 + cells×105/kg infused | Median, range | 0.54 (0.23–2.90) |
CD3 + cells×106/kg infused | Median, range | 25.45 (1.6–5.3) |
Vitality | Median, range | 91% (37–95%) |
Hematologic recovery | ||
median day to ANC > 0.5 × 109/L | Median day, range | 21.5 (12–38) |
median day to platelets > 20 × 109/L | Median day, range | 39.5 (19–90) |
median day to platelets > 50 × 109/L | Median day, range | 47 (34–150) |
Acute GVHD | Grade I, n (%) | 4 (17.4) |
Grade II, n (%) | 2 (8.7) | |
Grade III, n (%) | 1 (4.3) | |
Grade IV, n (%) | — | |
Chronic GVHD | Limited, n (%) | 3 (13.0) |
Extensive, n (%) | 1 (4.3) | |
